SAB BIOTHERAPEUTICS, INC. Operating Lease, Payments
SAB BIOTHERAPEUTICS, INC. (SABS) reported Operating Lease, Payments of $243.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. operating lease, payments for the quarter ending 2026-06-30 was $243.00K, a 7.60% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. operating lease, payments for the quarter ending 2026-03-31 was $280.00K, a 31.46% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. operating lease, payments for the quarter ending 2025-12-31 was $260.00K, a 103.13% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. operating lease, payments for the quarter ending 2025-09-30 was $264.00K, a 35.38% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. operating lease, payments for fiscal 2025 was $1.00M, a 25.00% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. operating lease, payments for fiscal 2024 was $800.00K, a 33.33% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. operating lease, payments for fiscal 2023 was $600.00K, a 50.00% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. operating lease, payments for fiscal 2022 was $1.20M, a 4.62% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $243.00K 10-Q · filed 2026-08-06 | $523.00K 10-Q · filed 2026-08-06 | $783.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $280.00K 10-Q · filed 2026-05-12 | $540.00K derived: sum of 2 quarters · filed 2026-05-12 | $804.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $260.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $524.00K derived: sum of 2 quarters · filed 2026-03-09 | $787.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.00M 10-K · filed 2026-03-09 |
| 2025-09-30 | $264.00K 10-Q · filed 2025-11-14 | $527.00K derived: sum of 2 quarters · filed 2026-08-06 | $740.00K 10-Q · filed 2025-11-14 | $868.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $263.00K 10-Q · filed 2026-08-06 | $476.00K 10-Q · filed 2026-08-06 | $604.00K derived: sum of 3 quarters · filed 2026-08-06 | $799.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $213.00K 10-Q · filed 2026-05-12 | $341.00K derived: sum of 2 quarters · filed 2026-05-12 | $536.00K derived: sum of 3 quarters · filed 2026-05-12 | $782.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $323.00K derived: sum of 2 quarters · filed 2026-03-09 | $569.00K derived: sum of 3 quarters · filed 2026-03-09 | $800.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $195.00K 10-Q · filed 2025-11-14 | $441.00K derived: sum of 2 quarters · filed 2025-11-14 | $672.00K 10-Q · filed 2025-11-14 | $918.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $246.00K 10-Q · filed 2025-08-07 | $477.00K 10-Q · filed 2025-08-07 | $723.00K derived: sum of 3 quarters · filed 2025-08-07 | $841.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $231.00K 10-Q · filed 2025-05-09 | $477.00K derived: sum of 2 quarters · filed 2025-05-09 | $595.00K derived: sum of 3 quarters · filed 2025-05-09 | $713.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $246.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $364.00K derived: sum of 2 quarters · filed 2025-03-31 | $482.00K derived: sum of 3 quarters · filed 2025-03-31 | $600.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $118.00K 10-Q · filed 2024-11-06 | $236.00K derived: sum of 2 quarters · filed 2024-11-06 | $354.00K 10-Q · filed 2024-11-06 | $624.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $118.00K 10-Q · filed 2024-08-08 | $236.00K 10-Q · filed 2024-08-08 | $506.00K derived: sum of 3 quarters · filed 2024-08-08 | $815.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $118.00K 10-Q · filed 2024-05-20 | $388.00K derived: sum of 2 quarters · filed 2024-05-20 | $697.00K derived: sum of 3 quarters · filed 2024-05-20 | $1.01M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $579.00K derived: sum of 2 quarters · filed 2024-03-29 | $888.00K derived: sum of 3 quarters · filed 2024-03-29 | $1.20M 10-K · filed 2024-03-29 |
| 2022-09-30 | $309.00K 10-Q · filed 2023-11-13 | $618.00K derived: sum of 2 quarters · filed 2023-11-13 | $930.00K 10-Q · filed 2023-11-13 | $1.24M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $309.00K 10-Q · filed 2023-08-21 | $621.00K 10-Q · filed 2023-08-21 | $931.00K derived: sum of 3 quarters · filed 2023-08-21 | $1.22M derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | $311.00K 10-Q · filed 2023-05-15 | $622.00K derived: sum of 2 quarters · filed 2023-05-15 | $907.00K derived: sum of 3 quarters · filed 2023-05-15 | $1.19M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $311.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | $596.00K derived: sum of 2 quarters · filed 2023-04-28 | $879.00K derived: sum of 3 quarters · filed 2023-04-28 | $1.15M 10-K/A · filed 2023-04-28 |
| 2021-09-30 | $285.00K 10-Q · filed 2022-11-14 | $568.00K derived: sum of 2 quarters · filed 2022-11-14 | $836.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $283.00K 10-Q · filed 2022-08-10 | $552.00K 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $268.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $564.00K 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |